美諾華(603538.SH):瑞舒伐他汀鈣原料藥獲歐洲CEP證書
格隆匯11月26日丨美諾華(603538.SH)公佈,近日,公司收到歐洲藥品質量管理局(以下簡稱“EDQM”)簽發的關於瑞舒伐他汀鈣(原料藥)的歐洲CEP證書(歐洲藥典適用性證書)。
該藥品適用於原發性高膽固醇血癥(Ⅱa型,包括雜合子家族性高膽固醇血癥)或混合性脂血障礙(Ⅱb型)患者在節食或鍛鍊療法不理想時的輔助治療。
瑞舒伐他汀是一種選擇性3-羥基-3-甲基戊二酰輔酶A(HMG-CoA)還原酶抑制劑,通過抑制HMG-CoA還原酶,減少肝細胞合成及儲存膽固醇,從而降低血中總膽固醇(TC)和低密度脂蛋白膽固醇(LDL-C)水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.